Article info

PDF
Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis

Authors

  1. Correspondence to Dr Martin K Schmid, Eye Clinic, Cantonal Hospital of Lucerne, Spitalstrasse, CH-6000 Lucerne 16, Switzerland; martin.schmid{at}luks.ch
View Full Text

Citation

Schmid MK, Bachmann LM, Fäs L, et al
Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis

Publication history

  • Received February 24, 2014
  • Revised March 24, 2014
  • Accepted May 9, 2014
  • First published June 11, 2014.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.